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Introduction 
Malacoplakia is a rare non-malignant inflammatory 
granulomatous disease of infectious etiology that is 
usually reported in the setting of deficient immune 
responsiveness such as in HIV infection [1-3]. It was 
ﬁrst described by Michaelis and Gutmann in 1902 [2, 
4] and one year later by von Hansemann who named 
the lesion malacoplakia from the Greek malakos 
(soft), and plaka (plaque), [5]. The first case of 
cutaneous malacoplakia was not reported until 1972 
by Leclerc and Bernier [6]. 
This literature search was conducted according to 
the Preferred Reporting Items for Systematic 
Reviews, or PRISMA, guidelines. Three databases, 
EMBASE, SCOPUS and MEDLINE (PubMed) were 
thoroughly searched using the following MESH key 
terms: “cutaneous” and “malacoplakia” or 
“malakoplakia.” Additional papers were also 
identified from the reference lists of the above 
retrieved papers and citations, as identified by Web 
of Science. The selection process was done through 
an initial screening of titles and abstracts, followed 
by evaluation of full text articles. According to the 
results, about 500 cases have been described in 
numerous anatomic locations. The most common 
site of occurrence is the genitourinary tract, but 
other locations have also been encountered, 
including the gastrointestinal tract, lungs, central 
nervous system, eyes, retroperitoneum, thyroid 
gland, lymph nodes, oropharynx, bones, joints, skin, 
and subcutaneous tissue [2, 7]; the cutaneous form is 
a less prevalent presentation of the disease and,  
Abstract 
Background: Malacoplakia is a rare acquired, 
infection-related granulomatous disorder, that may 
affect many systems, but typically occurs in the 
urinary tract. Cutaneous involvement is less 
prevalent, and most commonly presents with a 
perianal or genital region localization. Cutaneous 
malacoplakia is believed to be caused by an acquired 
bactericidal defect of macrophages in the setting of 
chronic infections and immunocompromised states. A 
diagnosis of cutaneous malacoplakia should be 
considered when encountering non-specific 
granulomatous lesions that are refractory to treatment. 
Histologic findings are marked by the presence of 
foamy macrophages containing the pathognomonic 
Michaelis-Gutman bodies.  
Objectives: The aim of this review is to discuss the 
current perspectives on the pathophysiology, clinical 
features, diagnosis, and treatment of this disease. We 
would also like to emphasize that the integration of clinical 
information, microscopic findings, and exclusion of other 
cutaneous granulomatous processes is necessary to 
accurately diagnose this exceedingly rare disease and 
provide opportunity for therapeutic intervention. 
Patients/Methods: Data for this work were collected 
from the published literature and textbooks. 
Results: Combined surgical excision and protracted 
antibiotic courses appear to have the highest success 
rate. Antibiotics should be culture specific, but drugs 
that easily permeate the macrophages appear to be 
the best choice.  
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most commonly occurs in the anogenital region [3, 
8]. Since its initial description, only 52 cases of 
primary cutaneous malacoplakia have been reported 
in the literature [9]. 
Etiology and pathogenesis 
The etiopathogenesis of malacoplakia has not been 
fully elucidated. However, it is believed to be 
secondary to a defect of the bactericidal capacity of 
macrophages after endocytosis [3, 10]. Inadequate 
microtubular function and phagolysosomal activity 
is related to deficiencies of beta-glucuronidase and 
intracellular cyclic guanosine monophosphate 
(cGMP) and leads to accumulation of partially 
digested bacteria in monocytes or macrophages [9, 
11]. The pathognomonic Michaelis-Gutman bodies 
are believed to represent the subsequent deposition 
of calcium and iron on non-exocytosed 
phagolysosomes [2, 10]. 
Additionally, there is a well-documented association 
between malacoplakia and immunosuppression 
(Figure 1). The majority of subjects are 
immunodeficient and include HIV-infected patients, 
patients with malignancy, patients with diabetes 
mellitus, and organ transplant recipients [3, 8]. 
In this setting of immunodeficiency, as many as 90% 
of patients have coliform bacteria detected in blood, 
urine or tissue, suggesting an opportunistic bacterial 
infection as the central event [3, 12]. The most 
commonly involved microorganisms include 
Escherichia coli (more than 2/3 of cases), Klebsiella, 
Proteus [2, 9], Mycobacterium tuberculosis, 
Mycobacterium avium, Staphylococcus aureus, 
Shigella, Rhodococcus equi and Enterococcus spp [3, 
9]. Malacoplakia with negative culture results have 
also been reported, but is presumably secondary to 
antibiotic therapy administration prior to diagnosis 
[5]. 
Epidemiology 
Cutaneous malacoplakia tends to occur in an older 
age group, most commonly affecting the age group 
of sixth to seventh decade, with the median age at 
the time of presentation being 53 years [2, 9]. 
Pediatric cases are exceptionally rare [3, 13]. 
Of the 52 cases of cutaneous malacoplakia reported 
so far, reports show a prevalence among men, with a 
male-to-female ratio of 2.3:1. There does not seem to 
be any racial predilection [2, 5]. The most common 
site of involvement is the anogenital area (41%), 
 
Figure 1. Etiopathogenesis of cutaneous malacoplakia. 
 
Figure 2. A yellow-erythematous-purple plaque at a site of 
frequent catheterization on a patient with chronic renal failure 
[3]. 
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trunk (20%), head and neck (20%), extremities (10%), 
and axillae (10%), [5, 14]., However, there have been 
reports of lesions that were distributed in more than 
one cutaneous site [5, 15-16]. 
Clinical features 
Clinically, cutaneous malacoplakia may present with 
a wide variety of findings; tissue biopsy is required 
for definitive diagnosis. Although the name 
describes its common clinical presentation as friable, 
yellow soft plaques, l  esions may also arise as yellow, 
skin-colored or erythematous papules, ulcerations 
[14, 17-18], draining abscesses and fistulas, 
subcutaneous nodules, nonhealing surgical wounds, 
or polypoid masses (Figure 2), [3, 5]. The most 
common clinical presentation in reported cases of 
cutaneous malacoplakia are mass-like lesions or 
nodules (Figure 1), (45%), occasionally complicated 
by abscess and ulceration formation in 18% and 23% 
of the cases, respectively [5, 10]. 
Histopathology 
The diagnosis of cutaneous malacoplakia is never 
made clinically but on specific histologic grounds, 
owing to its rarity and non-speciﬁc appearance, and 
also to exclude other important diseases in the 
differential diagnosis, such as malignancy [8, 20]. 
 
Figure 3. Typical lesions on the face of an immunocompromised 
patient [19]. Reprinted with permission from the Massachusetts 
Medical Society. 
 
Figure 4. Pathognomonic Michaelis-Gutmann body (arrow), [19]. 
H&E, 400×. Reprinted with permission from the Massachusetts 
Medical Society. 
 
Figure 5. Papanicolaou stain, 200×. Concentrically lamellated, 
darkly staining, calcified inclusion bodies (Michaelis-Gutmann 
bodies) inside the macrophages [22]. 
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Histopathologically, the disease is characterized by 
the presence of dermal sheets of enlarged foamy 
histiocytic cells containing an eccentric, 
hyperchromatic, round nucleus as well as fine 
eosinophilic granules (von Hansemann cells), [3]. There 
is a variable associated inflammatory infiltrate 
consisting mainly of scattered lymphocytes, 
immunoblasts, and neutrophils in the dermis [4-5]. 
However, this challenging diagnosis can only be 
made by identifying the pathognomonic Michaelis–
Gutmann  bodies, ﬁrst described in 1902 as targetoid, 
calcified, intracytoplasmic inclusion bodies (Figure 
4), [21]. These Michaelis–Gutmann bodies are 
believed to represent partially degraded remnants of 
bacterial organisms and stain positively with 
periodic acid Schiff, Von Kossa (calcium), Perl (iron) 
stains [3, 8], alizarin red, and Prussian blue stains 




The differential diagnosis of cutaneous malacoplakia 
commonly includes infectious diseases and malignant 
processes [8]. Infections to consider are deep fungal 
infections, actinomycosis, leishmaniasis, Whipple 
disease, as well as granulomatous infections such as 
tuberculosis and lepromatous leprosy [3, 5]. Neoplastic 
and reactive/reparative processes include eosinophilic 
granuloma (histiocytosis X), lymphoma, granular cell 
tumors, sarcoidosis, xanthomas, hidradenitis 
suppurativa, and foreign body granuloma [5, 23]. 
Treatment 
Successful treatment of malacoplakia largely 
depends on the extent of disease as well as the 
underlying condition of the patient. Owing to the 
lack of prospective comparative studies, many 
treatments have been reported, which vary from 
antibiotic therapy to surgical excision [3, 14]. 
However, protracted antibiotic courses directed 
against gram-negative bacteria, especially E. coli, 
combined with surgical excision appear to be the 
most common and successful approach [8, 10]. 
Administration of culture speciﬁc antibiotic therapy, 
antibiotics that reach high intracellular 
concentration within macrophages (e.g. quinolones 
and trimethoprim-sulfamethoxazole) as well as 
penicillins and clofazimine are associated with a high 
cure rate and appear to be the best empirical choice 
[8, 10, 24-25]. 
Alternative reported treatment options include 
muscarinic receptor agonists such as bethanechol 
chloride as well as ascorbic acid, both of which act to 
correct the decreased intracellular cGMP levels that 
are believed to interfere with inefficient microtubule 
functioning and bacterial killing [19, 26]. 
Discontinuation of immunosuppressive therapy, and 
treatment of any underlying medical conditions 
causing immunosuppression (e.g. HIV) are usually 
required for effective treatment of malacoplakia [3, 
27]. 
Prognosis 
Cutaneous malacoplakia usually presents as a 
benign self-limited condition that can undergo 
spontaneous regression, with a mean duration of 
skin lesions of 4-6 months [3, 10, 28]. Occasionally, 
the course of the disease may also be variable with 
frequent recurrences, local disfigurement, internal 
organ involvement, and significant morbidity 
associated with the chronicity of the condition and 
resistance to topical and systemic therapy [3, 10]. 
 
Conclusion 
Cutaneous malacoplakia is a rare entity, with as many 
as 52 cases reported in the literature, and poorly  
 
 
Figure 6. Periodic acid-Schiff stain, 400×. Dr. Koumoundourou, 
personal collection. 
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understood pathogenesis. Its rarity and non-speciﬁc 
appearance make it a challenging diagnosis. This 
chronic granulomatous disorder should be 
considered in the differential diagnosis of nodules, 
ulcers, and draining ulcers that are refractory to  
 
treatment, particularly in immunocompromised 
patients. 
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